Cited 58 times in
Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박준용 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 이재훈 | - |
dc.contributor.author | 이종두 | - |
dc.contributor.author | 최혜진 | - |
dc.contributor.author | 한광협 | - |
dc.contributor.author | 김도영 | - |
dc.date.accessioned | 2014-12-20T17:35:00Z | - |
dc.date.available | 2014-12-20T17:35:00Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 1478-3223 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/94874 | - |
dc.description.abstract | BACKGROUND: Sorafenib (Nexavar) is an orally active multikinase inhibitor that is approved for the treatment of hepatocellular carcinoma (HCC). In this study, we used (18) F-2-fluoro-2-deoxyglucose ((18) F-FDG) with positron emission tomography (PET) to predict the treatment outcome of sorafenib in patients with advanced HCC. MATERIALS AND METHODS: A total of 29 patients with HCC were included. Baseline (18) F-FDG PET scans were performed a median of 14 days before sorafenib treatment. Sorafenib was administered orally at a dose of 400 mg twice daily. For statistical analysis, the standardized uptake value (SUV) of the most hypermetabolic lesion was obtained and assigned as the SUVmax for each patient. RESULTS: Among 29 patients, one patient achieved partial remission and 14 patients showed stable disease. The overall survival (OS) and progression free survival (PFS) were 5.1 months [95% confidence interval (CI): 0.0-12.0] and 3.8 months (95% CI: 1.4-6.2). The multivariate analysis of OS showed that four indices, Eastern Cooperative Oncology Group performance status, α-fetoprotein (AFP) concentration, portal vein thrombosis and SUVmax were significant prognostic factors (P=0.030, P=0.024, P=0.020 and P=0.015 respectively). AFP concentration and SUVmax were independent prognostic factors for PFS, too (P=0.003 and P=0.026 respectively). When the patients were divided into two groups: low SUVmax (n=10; <5.00) and high SUVmax (n=19;≥ 5.00), the low SUV group showed significantly longer OS and PFS (P=0.023 and P=0.042 respectively). CONCLUSION: Our study showed that the degree of FDG uptake is an independent prognostic factor in patients with HCC who undergo sorafenib treatment. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1144~1149 | - |
dc.language | English | - |
dc.publisher | Wiley-Blackwell | - |
dc.relation.isPartOf | LIVER INTERNATIONAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Administration, Oral | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Agents/administration & dosage | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use* | - |
dc.subject.MESH | Benzenesulfonates/administration & dosage | - |
dc.subject.MESH | Benzenesulfonates/therapeutic use* | - |
dc.subject.MESH | Carcinoma, Hepatocellular/diagnostic imaging* | - |
dc.subject.MESH | Carcinoma, Hepatocellular/drug therapy* | - |
dc.subject.MESH | Carcinoma, Hepatocellular/enzymology | - |
dc.subject.MESH | Carcinoma, Hepatocellular/mortality | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorodeoxyglucose F18* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Liver Neoplasms/diagnostic imaging* | - |
dc.subject.MESH | Liver Neoplasms/drug therapy* | - |
dc.subject.MESH | Liver Neoplasms/enzymology | - |
dc.subject.MESH | Liver Neoplasms/mortality | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Niacinamide/analogs & derivatives | - |
dc.subject.MESH | Phenylurea Compounds | - |
dc.subject.MESH | Positron-Emission Tomography* | - |
dc.subject.MESH | Predictive Value of Tests | - |
dc.subject.MESH | Proportional Hazards Models | - |
dc.subject.MESH | Protein Kinase Inhibitors/administration & dosage | - |
dc.subject.MESH | Protein Kinase Inhibitors/therapeutic use* | - |
dc.subject.MESH | Pyridines/administration & dosage | - |
dc.subject.MESH | Pyridines/therapeutic use* | - |
dc.subject.MESH | Radiopharmaceuticals* | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Risk Assessment | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Young Adult | - |
dc.title | Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Nuclear Medicine (핵의학) | - |
dc.contributor.googleauthor | Jae Hoon Lee | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Kwang-Hyub Han | - |
dc.contributor.googleauthor | Hyo Jung Seo | - |
dc.contributor.googleauthor | Jong Doo Lee | - |
dc.contributor.googleauthor | Hye Jin Choi | - |
dc.identifier.doi | 10.1111/j.1478-3231.2011.02541.x | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A03138 | - |
dc.contributor.localId | A04219 | - |
dc.contributor.localId | A04268 | - |
dc.contributor.localId | A03093 | - |
dc.contributor.localId | A00385 | - |
dc.relation.journalcode | J02171 | - |
dc.identifier.eissn | 1478-3231 | - |
dc.identifier.pmid | 21745288 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1111/j.1478-3231.2011.02541.x/abstract | - |
dc.subject.keyword | 18F | - |
dc.subject.keyword | FDG PET | - |
dc.subject.keyword | hepatocellular carcinoma | - |
dc.subject.keyword | sorafenib | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.alternativeName | Lee, Jae Hoon | - |
dc.contributor.alternativeName | Lee, Jong Doo | - |
dc.contributor.alternativeName | Choi, Hye Jin | - |
dc.contributor.alternativeName | Han, Kwang Hyup | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Lee, Jong Doo | - |
dc.contributor.affiliatedAuthor | Choi, Hye Jin | - |
dc.contributor.affiliatedAuthor | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Lee, Jae Hoon | - |
dc.contributor.affiliatedAuthor | Kim, Do Young | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 31 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1144 | - |
dc.citation.endPage | 1149 | - |
dc.identifier.bibliographicCitation | LIVER INTERNATIONAL, Vol.31(8) : 1144-1149, 2011 | - |
dc.identifier.rimsid | 27817 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.